Adalimumab: A Review of the Reference Product and Biosimilars

Biosimilars
doi 10.2147/bs.s98177
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Pmu4 - The Safety of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comment On: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Drugs
Pharmacology
2018English

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017English

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Arthritis Research & Therapy
2019English

Glycosylation Pattern and in Vitro Bioactivity of Reference Follitropin Alfa and Biosimilars

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2019English

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review

Frontiers in Pharmacology
Pharmacology
2019English

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence

BioDrugs
MedicineBiotechnologyPharmacology
2017English

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence

BioDrugs
MedicineBiotechnologyPharmacology
2016English

Dynamic Software Product Line Engineering: A Reference Framework

International Journal of Software Engineering and Knowledge Engineering
Computer GraphicsComputer NetworksCommunicationsComputer-Aided DesignArtificial IntelligenceSoftware
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy